The Provision of Medicines in Russia: Budget, Balance and Outcome
Issues for Discussion
- Value-based medicine is a new reality in the world. What could those values be: health indicators, patient's condition, impact on the health system, economy and society as a whole?
- Cost management methods - cost containment or optimization?
- Is it possible and justified to introduce in Russia mechanisms for effective interaction between the State and business within the drug procurement process, where payment is made based on the efficacy of treatment?
- Conditions required for the introduction of such a system: legislation, regulatory environment in public procurement, monitoring, recording and quality evaluation system
Director, Center of Healthcare Expert Evaluation and Quality Control of the Ministry of Health of the Russian Federation
Minister of Healthcare of the Russian Federation
Company Group Chairman, Janssen Pharmaceutical Companies, Johnson & Johnson
Senior Vice-President and Region Head, Emerging Growth Markets, Novartis Oncology
Frank R. Lichtenberg
Professor of Business, Columbia University Graduate School of Business; Research Associate, National Bureau of Economic Research
Director, Social Development Department, Ministry of Economic Development of the Russian Federation
Vice-President, Managing Director, MSD Russia
Minister of Healthcare of the Rostov region
General Director, Almazov National Medical Research Centre